Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.celrep.2021.108940 http://scihub22266oqcxt.onion/10.1016/j.celrep.2021.108940 33784499!7969873!33784499     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Cell+Rep 2021 ; 35 (1): 108940 Nephropedia Template TP {{tp|p=33784499|t=2021. Antiviral drug screen identifies DNA-damage response inhibitor as potent blocker of SARS-CoV-2 replication |pdf=|usr=}}{{33784499}} gab.com Text Antiviral drug screen identifies DNA-damage response inhibitor as potent blocker of SARS-CoV-2 replication JO: Cell Rep http://www.kidney.de/pget.php?&tw=1&pmid=33784499 #FOAvip SARS-CoV-2 has currently precipitated the COVID-19 global health crisis. We developed a medium-throughput drug-screening system and identified a small-molecule library of 34 of 430 protein kinase inhibitors that were capable of inhibiting the SARS-CoV-2 cytopathic effect in human epithelial cells. These drug inhibitors are in various stages of clinical trials. We detected key proteins involved in cellular signaling pathways mTOR-PI3K-AKT, ABL-BCR/MAPK, and DNA-damage response that are critical for SARS-CoV-2 infection. A drug-protein interaction-based secondary screen confirmed compounds, such as the ATR kinase inhibitor berzosertib and torin2 with anti-SARS-CoV-2 activity. Berzosertib exhibited potent antiviral activity against SARS-CoV-2 in multiple cell types and blocked replication at the post-entry step. Berzosertib inhibited replication of SARS-CoV-1 and the Middle East respiratory syndrome coronavirus (MERS-CoV) as well. Our study highlights key promising kinase inhibitors to constrain coronavirus replication as a host-directed therapy in the treatment of COVID-19 and beyond as well as provides an important mechanism of host-pathogen interactions. Twit Text FOAVip Antiviral drug screen identifies DNA-damage response inhibitor as potent blocker of SARS-CoV-2 replication ????Cell Rep http://www.kidney.de/pget.php?&tw=1&pmid=33784499 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33784499 #FOAvip English Wikipedia <ref>{{Cite pmid|33784499}}</ref> Antiviral drug screen identifies DNA-damage response inhibitor as potent blocker of SARS-CoV-2 replication #MMPMID33784499 Garcia G Jr; Sharma A; Ramaiah A; Sen C; Purkayastha A; Kohn DB; Parcells MS; Beck S; Kim H; Bakowski MA; Kirkpatrick MG; Riva L; Wolff KC; Han B; Yuen C; Ulmert D; Purbey PK; Scumpia P; Beutler N; Rogers TF; Chatterjee AK; Gabriel G; Bartenschlager R; Gomperts B; Svendsen CN; Betz UAK; Damoiseaux RD; Arumugaswami V Cell Rep 2021[Apr]; 35 (1): 108940 PMID33784499show ga SARS-CoV-2 has currently precipitated the COVID-19 global health crisis. We developed a medium-throughput drug-screening system and identified a small-molecule library of 34 of 430 protein kinase inhibitors that were capable of inhibiting the SARS-CoV-2 cytopathic effect in human epithelial cells. These drug inhibitors are in various stages of clinical trials. We detected key proteins involved in cellular signaling pathways mTOR-PI3K-AKT, ABL-BCR/MAPK, and DNA-damage response that are critical for SARS-CoV-2 infection. A drug-protein interaction-based secondary screen confirmed compounds, such as the ATR kinase inhibitor berzosertib and torin2 with anti-SARS-CoV-2 activity. Berzosertib exhibited potent antiviral activity against SARS-CoV-2 in multiple cell types and blocked replication at the post-entry step. Berzosertib inhibited replication of SARS-CoV-1 and the Middle East respiratory syndrome coronavirus (MERS-CoV) as well. Our study highlights key promising kinase inhibitors to constrain coronavirus replication as a host-directed therapy in the treatment of COVID-19 and beyond as well as provides an important mechanism of host-pathogen interactions. |*COVID-19 Drug Treatment[MESH] |*DNA Damage[MESH] |A549 Cells[MESH] |Animals[MESH] |Antiviral Agents/*pharmacology[MESH] |COVID-19/metabolism/pathology[MESH] |Chlorocebus aethiops[MESH] |Drug Evaluation, Preclinical[MESH] |HEK293 Cells[MESH] |HeLa Cells[MESH] |Humans[MESH] |Isoxazoles/*pharmacology[MESH] |MAP Kinase Signaling System/drug effects[MESH] |Middle East Respiratory Syndrome Coronavirus/metabolism[MESH] |Pyrazines/*pharmacology[MESH] |SARS-CoV-2/*physiology[MESH] |Vero Cells[MESH]Antiviral drug screen identifies DNA-damage response inhibitor as pote(epmc).pdf DeepDyve Pubget Overpricing